<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bhatt, Deepak L.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Similar 12-Month BP Reductions with Renal Denervation and Sham Procedure</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">21-22</style></pages><abstract><style  face="normal" font="default" size="100%">The Renal Denervation in Patients With Uncontrolled Hypertension trial [SYMPLICITY HTN-3; NCT01418261] was the first randomized, blinded, sham-controlled clinical trial of renal denervation for treatment-resistant hypertension. In addition to the blinding and sham control, post hoc analyses have identified potential factors that may account for the negative results, including the patient population and procedural variability, which are discussed in this 12-month post hoc analysis.</style></abstract><number><style face="normal" font="default" size="100%">30</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>